How much less people eat
In controlled feeding studies, energy intake fell by roughly 16 to 39% compared with placebo across liraglutide, semaglutide and tirzepatide.[1] At a free-choice lunch, people on semaglutide 2.4 mg ate 35% less than the placebo group at week 20,[2] and total intake was still 24% lower at week 60 in a longer trial.[3]
Where the gaps show up
One study recorded three days of eating in 69 US adults on GLP-1 drugs. Average intake was 1,748 kcal a day. Fibre averaged 14.5 g against a 28 g reference, and several minerals and vitamins (calcium, iron, magnesium, potassium, vitamin D and others) fell below recommended amounts. Only 43% reached 1.2 g of protein per kg of body weight.[4] This study was funded by a supplement retailer and all authors were its employees, which is a reason for caution; it is small, but it is also the only direct measurement we found.[4]
Protein: the numbers and where they come from
The protein ranges you see online, 1.2 to 1.6 g per kg a day or at least 60 to 75 g a day, come from expert advisories and reviews, not from trials that gave people on GLP-1 drugs different protein amounts and measured the result.[5][6] The American Diabetes Association's 2026 standards set at least 0.8 g per kg a day and recommend counselling and monitoring nutrition during intentional weight loss.[7] Why protein gets attention is the lean-mass question: about a quarter of the weight lost in the tirzepatide body-scan substudy was lean mass, the same share as in the placebo group.[8]
Common advice, graded
| Advice | Where it comes from | Tested in GLP-1 users? |
|---|---|---|
| Smaller meals; stop when full | Trial protocols and tolerability reviews[9][10] | No separate test |
| Less fatty and greasy food | Expert consensus, for nausea[10] | No |
| Protein at each meal | Expert advisories[5][6] | No |
| Fluids between meals, not with them | Bariatric surgery guidance, graded at the lowest evidence level[11] | No |
| Enough fluids through the day | Label warnings on dehydration and kidney injury[12][13] | Label-based |
No randomized GLP-1 trial has measured fibre, micronutrient status, fluid timing, meal frequency or meal replacements as an outcome.[1] This site does not recommend supplements or products; whether you need one is a question for your clinician or a registered dietitian, ideally with a blood test.
Fluids are a safety issue
Both the Wegovy and Zepbound labels warn about kidney injury from dehydration when vomiting or diarrhea combine with drinking less.[12][13] When appetite and thirst are both down, fluids are the one piece of eating advice that is backed by a label warning.
Heard vs evidence
The short version
Short on the way. A 35-second captioned version of this page is in production for the Fewer Bites channel. It will be embedded here when it is live.
Questions to bring to your prescriber
Print these or screenshot them. They are conversation starters, not a checklist of things to do.
- Is a referral to a registered dietitian available to me?
- What protein and fluid amounts make sense for my weight, kidneys and other conditions?
- Would blood tests for iron, vitamin B12 or vitamin D be useful for me?
Education, not advice. This page explains what trials, labels and guidelines report. It does not tell anyone to start, change or stop a medicine. Your prescriber knows your history; this page does not.
Sources
- Christensen S et al. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review. Obesity Pillars 2024. primary read via dossier · review
- Friedrichsen M et al. Effect of semaglutide 2.4 mg on gastric emptying, appetite and energy intake in adults with obesity. Diabetes Obes Metab 2021;23:754–62. primary read · RCT · industry-funded
- Randomized 60-week trial of semaglutide 2.4 mg on energy intake and appetite (NCT05548647). secondary · figures via Fewer Bites eating dossier
- Johnson B et al. Dietary intake of adults using GLP-1 receptor agonists. Front Nutr 2025 (funded by GNC; authors GNC employees). primary read via dossier · cross-sectional · industry-funded
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy: joint advisory from ACLM, ASN, OMA and TOS. Am J Lifestyle Med 2025. primary read via Fewer Bites eating dossier · expert consensus
- Almandoz JP et al. Nutritional considerations with antiobesity medications. Obesity 2024. secondary · expert review
- American Diabetes Association. Standards of Care in Diabetes 2026, Section 8: Obesity and weight management. primary read · guideline
- Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1 (DXA substudy). Diabetes Obes Metab 2025. primary read via Fewer Bites muscle dossier · RCT substudy · industry-funded
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg: post hoc analysis of STEP 1–3. Diabetes Obes Metab 2022;24:94–105. primary read · post hoc · industry-funded
- Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events with GLP-1 receptor agonists. J Clin Med 2022 (Novo Nordisk-funded). secondary · expert consensus
- Mechanick JI et al. AACE/TOS/ASMBS/OMA/ASA clinical practice guidelines for perioperative support of patients undergoing bariatric procedures, 2019 update. Obesity 2020. guideline · fluid-timing advice graded lowest level
- Novo Nordisk / FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised 06/2026. label
- Eli Lilly / FDA. Zepbound (tirzepatide) prescribing information, revised 08/2026. label